847871-99-2 Usage
General Description
Lenalidomide (hemihydrate) is a pharmaceutical compound used in the treatment of multiple myeloma, myelodysplastic syndromes, and certain types of lymphoma. It is a derivative of thalidomide and works by modulating the immune system and inhibiting the growth of cancer cells. Lenalidomide is believed to exert its anti-cancer effects by targeting various pathways involved in cell proliferation, angiogenesis, and inflammation. The hemihydrate form of the drug is a crystalline structure that is more stable and has better shelf-life compared to the anhydrous form. It is administered orally in the form of capsules and is often used in combination with other chemotherapy drugs for maximum efficacy. Potential side effects of lenalidomide (hemihydrate) include myelosuppression, thrombosis, and birth defects, so it is important for patients to be closely monitored during treatment.
Check Digit Verification of cas no
The CAS Registry Mumber 847871-99-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,4,7,8,7 and 1 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 847871-99:
(8*8)+(7*4)+(6*7)+(5*8)+(4*7)+(3*1)+(2*9)+(1*9)=232
232 % 10 = 2
So 847871-99-2 is a valid CAS Registry Number.
847871-99-2Relevant articles and documents
amine to the crystal and its preparation method
-
Paragraph 0037; 0038, (2017/06/24)
The invention provides a hemihydrate crystal form V of lenalidomide, which has characteristic X diffraction ray peaks in the X-ray powder diffractogram when 2theta is 12.0+/-0.2 degrees, 13.7+/-0.2 degrees, 24.7+/-0.2 degrees and 27.5+/-0.2 degrees. The invention also provides a preparation method of the hemihydrate crystal form V of lenalidomide, which comprises the following steps: (1) dissolving lenalidomide in a polar organic solvent, wherein the polar organic solvent is selected from one or more of aliphatic sulfone solvents aliphatic amide solvents; (2) dropwisely adding the solution obtained in the step (1) into 0-30 DEG C water to precipitate the expected crystal form from the solution; and (3) separating the crystal solid obtained in the step (2). The hemihydrate crystal form of lenalidomide has the advantages of high yield, high purity and high stability.
